(Q54457707)

English

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. (English)

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tadeusz Pieńkowski

12

object named as

Tadeusz Pienkowski

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

author name string

Istvan Lang

1

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Thomas Brodowicz

2

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Larisa Ryvo

3

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Zsuzsanna Kahan

4

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Richard Greil

5

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Semir Beslija

6

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Salomon M Stemmer

7

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Bella Kaufman

8

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Zanete Zvirbule

9

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Günther G Steger

10

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Bohuslav Melichar

11

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Daniela Sirbu

13

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Diethelm Messinger

14

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Christoph Zielinski

15

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Central European Cooperative Oncology Group

16

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

publication date

10 January 2013

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Lancet Oncology Commission

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

14

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

2

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

125-133

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

1st International consensus guidelines for advanced breast cancer (ABC 1).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress against solid tumors in danger: the metastatic breast cancer example

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970566-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70566-1

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

1 reference

Europe PubMed Central

30 May 2018

http://europepmc.org/abstract/MED/23312888

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54457707&oldid=1672304013"